KEYTRUDA 25 mg/mL concentrate for solution for infusion. clinical trials
15 indexed studies · 9 currently recruiting
- RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
This clinical trial is testing a new drug called petosemtamab combined with an established immunotherapy called pembrolizumab (Keytruda). It aims to find out if this combination is safe and effective at shrinking tumours in adults diagnosed with non-small cell lung cancer.
For: Non Small Cell Lung CancerSpain · Belgium · Netherlands - RecruitingTherapeutic exploratory (Phase II)
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients
This study tests whether an immunotherapy drug called Keytruda can help women with ovarian, fallopian tube, or peritoneal cancer. It looks at women whose cancer has returned after standard platinum chemotherapy and whose tumours have a specific protein marker, measuring if the treatment helps them live longer.
For: Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patientsItaly - RecruitingTherapeutic exploratory (Phase II)
Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer - Pembro-SRT
This study looks at combining radiotherapy with an immunotherapy medicine called pembrolizumab (Keytruda) for men with prostate cancer. It is for people whose PSA levels stay detectable or begin rising again after surgery to remove the prostate. Researchers want to see if this combination safely clears the cancer.
For: recurrent prostate cancerGermany - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
This study is testing a new medicine called Keytruda for people in the UK with certain types of lymphoma that have come back or not responded to previous treatments. It aims to see how well Keytruda shrinks the lymphoma and if it is safe.
For: Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell LymphomaPoland · Italy · Czechia - RecruitingPhase I and Phase II (Integrated)- Other
LAVA1207-001/LAVA1207-002 A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer
This study is testing a new drug, LAVA-1207, for men with prostate cancer that has spread and isn't responding to other treatments. Researchers want to see if it's safe, how well it works, and if combining it with other drugs like Pembrolizumab helps shrink the cancer.
For: Prostate Cancer, Prostate CancerSpain · Netherlands - RecruitingTherapeutic exploratory (Phase II)
(APOLLO)Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study
This study is looking at a new way to treat vulvar squamous cell carcinoma before surgery. Researchers are testing a drug called Keytruda to see if it can shrink tumours and how it affects the body's immune cells, hoping for better treatment outcomes.
For: Vulvar squamous cell carcinomaNetherlands - RecruitingTherapeutic exploratory (Phase II)
Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)
This study looks at a new treatment called pembrolizumab combined with paclitaxel for some women with advanced breast cancer. It's for those whose cancer has grown even after previous treatments. Researchers want to see how well it shrinks tumours.
For: Pre and post-menopausal women with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancerSpain - RecruitingTherapeutic exploratory (Phase II)
PEVOsq: Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma
This study looks at a new combination treatment for certain skin cancers that have returned or spread. It uses a specific drug to see how many patients respond positively to the treatment.
For: Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anusFrance - RecruitingTherapeutic exploratory (Phase II)
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
This study is testing a new cancer medicine, MK-1088, sometimes with an existing medicine called Pembrolizumab (Keytruda). We want to find out if it's safe for people with advanced solid tumours and how well it's tolerated. It's an early-stage study focusing on safety.
For: Treatment of advanced/metastatic solid tumorsDenmark - AuthorisedTherapeutic exploratory (Phase II)
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)
RESET C2 is a study looking at a new way to treat early colon cancer that has a specific genetic marker (dMMR). It uses an immunotherapy drug (Keytruda) before surgery, aiming to shrink the cancer so surgery might not be needed, or to make it less extensive.
For: Localised dMMR Colon CancerDenmark - AuthorisedPhase I and Phase II (Integrated)- Bioequivalence Study
PHASE 1B/II TRIAL OF CHECKPOINT INHIBITOR (PEMBROLIZUMAB AND ANTI PD-1 ANTIBODY) PLUS STANDARD IMRT IN HPV INDUCED STAGE III SQUAMOUS CELL CARCINOMA OF ANUS
This study looks at a new way to treat anal cancer caused by HPV. It combines a standard radiation and chemotherapy treatment with a new drug called pembrolizumab (Keytruda). The main goal is to see if this combination treatment is safe and well-tolerated.
For: Anal cancerNorway - AuthorisedTherapeutic exploratory (Phase II)
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY
This study looks at a new way to treat high-risk skin cancer (melanoma) using a drug called Keytruda before surgery. Researchers want to see how well Keytruda shrinks the cancer and if it's safe for patients.
For: melanomaFrance - AuthorisedTherapeutic exploratory (Phase II)
A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer).
This study looks at a medicine called Pembrolizumab (Keytruda) for people with a type of lung cancer that can't be removed by surgery. It aims to see if this medicine helps people live longer after they've had chemotherapy and radiation.
For: non Small Cell Lung CancerItaly - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A phase I/II trial of IOMX-0675 a fully human monoclonal antibody selectively inhibiting LILRB1/2 alone or in combination with pembrolizumab in patients with previously treated advanced/metastatic solid tumors (LIMNOS)
This study is testing a new drug (IOMX-0675) alone or with an existing treatment (Keytruda) for advanced cancers. The main goal is to find a safe and effective dose, and see how well it works and if it causes side effects.
For: Advanced/metastatic solid tumorsSpain - AuthorisedTherapeutic exploratory (Phase II)
MITO CERV4: Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and cervical lesions
This study looks at how well a medicine called Keytruda works for women with changes in their cervix or vulva caused by HPV, which could lead to cancer. Researchers want to see if this medicine can help these changes disappear before surgery.
For: Patients with pre neoplastic high grade HPV-related vulvar and cervical lesionsItaly